Referenced in: none

Automatically associated channels: ClC4

Title: Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody.

Authors: Paul B Chapman

Journal, date & volume: , 2003 Jun , 4, 710-5

PubMed link: http://www.ncbi.nlm.nih.gov/pubmed/12901230

Abstract
GD3, a ganglioside expressed on tumors of neuroectodermal origin such as melanoma and small-cell lung carcinoma (SCLC), is an attractive vaccine target but is poorly immunogenic. Our group has pursued several strategies designed to immunize patients against GD3 including using BEC2, an anti-idiotypic monoclonal antibody that mimics GD3. Pilot trials in melanoma and SCLC indicate that BEC2 can induce an anti-GD3 antibody response in a subset of patients and also suggests that immunization with BEC2 is associated with improved survival. A phase III trial is underway in SCLC patients to determine the effects of BEC2 on overall survival.